Long-term response with everolimus for metastatic renal cell carcinoma refractory to sunitinib

por Molina, Ana M., Ginsberg, Michelle S., Motzer, Robert J.
Publicado 2010

A brief symptom index for advanced renal cell carcinoma

por Eton, David T, Cella, David, Bacik, Jennifer, Motzer, Robert J
Publicado 2006

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor

por Khosravan, Reza, Motzer, Robert J., Fumagalli, Elena, Rini, Brian I.
Publicado 2016

Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma

por Motzer, Robert J., Escudier, Bernard, Powles, Thomas, Scheffold, Christian, Choueiri, Toni K.
Publicado 2018

Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) for Lenvatinib plus Everolimus Versus Everolimus Monotherapy in Patients with Advanced Renal Cell Carcinoma

por Lee, Chung-Han, Wan, Yin, Smith, Alan, Xie, Ran, Motzer, Robert J.
Publicado 2021

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

por Yang, Lin, Alyasova, Anna, Ye, Dingwei, Ridolfi, Antonia, Dezzani, Luca, Motzer, Robert J.
Publicado 2018

A Quality-adjusted Time Without Symptoms or Toxicity (Q-TWiST) Analysis of Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma (aRCC)

por Shah, Ruchitbhai, Botteman, Marc, Solem, Caitlyn T., Luo, Linlin, Doan, Justin, Cella, David, Motzer, Robert J.
Publicado 2019

Neutrophil Chemokines Secreted by Tumor Cells Mount a Lung Antimetastatic Response during Renal Cell Carcinoma Progression

por López-Lago, Miguel A., Posner, Shai, Thodima, Venkata J., Molina, Ana M., Motzer, Robert J., Chaganti, RSK
Publicado 2012

A case for the use of receiver operating characteristic analysis of potential clinical efficacy biomarkers in advanced renal cell carcinoma

por English, Patricia A, Williams, J Andrew, Martini, Jean-François, Motzer, Robert J, Valota, Olga, Buller, Richard E
Publicado 2016

Sunitinib Does Not Accelerate Tumor Growth in Patients with Metastatic Renal Cell Carcinoma

por Blagoev, Krastan B., Wilkerson, Julia, Stein, Wilfred D., Motzer, Robert J., Bates, Susan E., Fojo, A. Tito
Publicado 2013

Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

por Stein, Andrew, Wang, Wenping, Carter, Alison A, Chiparus, Ovidiu, Hollaender, Norbert, Kim, Hyewon, Motzer, Robert J, Sarr, Celine
Publicado 2012

Sarcomatoid renal cell carcinoma: biology, natural history and management

por Blum, Kyle A., Gupta, Sounak, Tickoo, Satish K., Chan, Timothy A., Russo, Paul, Motzer, Robert J., Karam, Jose A., Hakimi, A. Ari
Publicado 2020

Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins

por DePrimo, Samuel E, Bello, Carlo L, Smeraglia, John, Baum, Charles M, Spinella, Dominic, Rini, Brian I, Michaelson, M Dror, Motzer, Robert J
Publicado 2007

Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

por Rini, Brian I., Cohen, Darrel P., Lu, Dongrui R., Chen, Isan, Hariharan, Subramanian, Gore, Martin E., Figlin, Robert A., Baum, Michael S., Motzer, Robert J.
Publicado 2011

Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

por Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J
Publicado 2016

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors

por Taylor, Matthew H., Lee, Chung-Han, Makker, Vicky, Rasco, Drew, Dutcus, Corina E., Wu, Jane, Stepan, Daniel E., Shumaker, Robert C., Motzer, Robert J.
Publicado 2020

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma

por Murphy, Danielle A, Rini, Brian I, Escudier, Bernard, Motzer, Robert J, Wang, Panpan, Li, Sherry, Williams, J Andrew, Tarazi, Jamal C, Martini, Jean-Francois
Publicado 2020

Exploratory analysis of the platelet-to-lymphocyte ratio prognostic value in the adjuvant renal cell cancer setting

por Patel, Anup, Ravaud, Alain, Motzer, Robert J, Pantuck, Allan J, Staehler, Michael, Escudier, Bernard, Martini, Jean-François, Lechuga, Mariajose, Lin, Xun, George, Daniel J
Publicado 2020

Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy...

por Motzer, Robert J., Hutson, Thomas E., Hudes, Gary R., Figlin, Robert A., Martini, Jean-Francois, English, Patricia A., Huang, Xin, Valota, Olga, Williams, J. Andrew
Publicado 2014

Nivolumab plus ipilimumab versus sunitinib in previously untreated advanced renal-cell carcinoma: analysis of Japanese patients in CheckMate 214 with extended follow-up

por Tomita, Yoshihiko, Kondo, Tsunenori, Kimura, Go, Inoue, Takamitsu, Wakumoto, Yoshiaki, Yao, Masahiro, Sugiyama, Takayuki, Oya, Mototsugu, Fujii, Yasuhisa, Obara, Wataru, Motzer, Robert J, Uemura, Hirotsugu
Publicado 2019